Dianthus Therapeutics, Inc.
DNTH
Rang in aandelen
#3820
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Aandeelprijs
$77.97
Marktkapitalisatie
$4.36B
Verandering (1 dag)
4.60%
Verandering (1 jaar)
116.58%
Land
US
Handel Dianthus Therapeutics, Inc. (DNTH)
Categorie
Healthcare
P/B-ratio voor Dianthus Therapeutics, Inc. (DNTH)
P/B-ratio op October 2026 TTM: 3.57
Volgens de meest recente financiële rapporten en aandelenkoers van Dianthus Therapeutics, Inc. is de huidige P/B-ratio (TTM) 3.57. Eind 2023 had het bedrijf een P/B-ratio van 0.32.
P/B-ratiohistoriek voor Dianthus Therapeutics, Inc. van 2016 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 3.57 | 73.49% |
| 2024 | 2.06 | 549.15% |
| 2023 | 0.32 | -159.46% |
| 2022 | -0.53 | -137.87% |
| 2021 | 1.41 | -41.09% |
| 2020 | 2.39 | -39.79% |
| 2019 | 3.97 | 204.85% |
| 2018 | 1.30 | -87.23% |
| 2017 | 10.21 | -82.03% |
| 2016 | 56.80 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | 74.91% |
US
|
|
| 13.2547 | 270.87% |
US
|
|
| 4.208 | 17.74% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 72.99% |
NL
|
